Skip to main content
Clinical Trials/NCT06441292
NCT06441292
Not Yet Recruiting
N/A

Study on Prostate Targeted Biopsy Precision Navigation Method Based on Multi-Modal Image Fusion Deep Learning Using Multi-Parameter Ultrasound and MRI

Shanghai East Hospital1 site in 1 country602 target enrollmentJuly 1, 2024
ConditionsProstate Cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Shanghai East Hospital
Enrollment
602
Locations
1
Primary Endpoint
The detection rate of clinically significant prostate cancer by targeted biopsy alone
Status
Not Yet Recruiting
Last Updated
last year

Overview

Brief Summary

This study is a prospective randomized controlled clinical trial aimed at comparing the detection rates of clinically significant prostate cancer between conventional biopsy methods and AI-assisted biopsy methods in patients undergoing initial prostate biopsy who meet the indications for prostate biopsy.

Detailed Description

This study is a prospective randomized controlled clinical trial designed to investigate the efficacy of AI-assisted biopsy methods compared to conventional biopsy methods in detecting clinically significant prostate cancer. The target population includes patients undergoing their initial prostate biopsy who meet established indications for prostate biopsy.

Registry
clinicaltrials.gov
Start Date
July 1, 2024
End Date
July 15, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Sponsor
Shanghai East Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • PSA \> 4 ng/ml and/or abnormal DRE
  • Sign the informed consent

Exclusion Criteria

  • Have acute or chronic prostatitis
  • Contraindications to prostate biopsy
  • Contraindications to MRI
  • Other reasons that not suitable for this trial

Outcomes

Primary Outcomes

The detection rate of clinically significant prostate cancer by targeted biopsy alone

Time Frame: 2-3 weeks post-biopsy

The proportion of men with a Gleason score ≥3+4 in pathological assessment for targeted biopsy samples

Secondary Outcomes

  • The detection rate of clinically significant prostate cancer by targeted biopsy combined with template biopsy(2-3 weeks post-biopsy)
  • The detection rate of any prostate cancer by targeted biopsy alone(2-3 weeks post-biopsy)
  • The detection rate of any prostate cancer by targeted biopsy combined with template biopsy(2-3 weeks post-biopsy)

Study Sites (1)

Loading locations...

Similar Trials